Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
- 1 August 1997
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33, S7-S10
- https://doi.org/10.1016/s0959-8049(97)90002-2
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Treatment of patients resistant to anthracycline therapyAnti-Cancer Drugs, 1996
- First-line treatment of metastatic breast cancerAnti-Cancer Drugs, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Resistence to cytotoxic therapy: A speculative overviewAnnals of Oncology, 1995
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with taxol and conventional antineoplastic agentsEuropean Journal Of Cancer, 1993
- Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cellsAnti-Cancer Drugs, 1992